Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172652 · ClinicalTrials.gov registry record · Phase 4
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
A Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder, sponsored by VA Palo Alto Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 3
- Study locations
NCT01172652 is a Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder that has completed, run by VA Palo Alto Health Care System. The registered enrollment target is 49 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01172652, a Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder, has completed, sponsored by VA Palo Alto Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 3
- Study locations
Study Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziprasidone
Study Locations (3)
California
- VA Palo Alto Health Care System & Stanford School of Medicine - Palo Alto
Florida
- University of South Florida Institute for Research in Psychiatry - Tampa
Ohio
- Lindner Center of Hope University of Cincinnati Medical Center - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172652
The ClinicalTrials.gov registry entry for NCT01172652 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (85% lower). The listed sponsor is VA Palo Alto Health Care System, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01172652 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01172652 about?
NCT01172652 is a clinical study titled "Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)". The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxie...
What is the current status of trial NCT01172652?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2010-04. Estimated completion is 2011-10.
What conditions does trial NCT01172652 study?
This clinical trial studies the following conditions: Bipolar Disorder, Generalized Anxiety Disorder, Panic Disorder.
What interventions are being tested in trial NCT01172652?
The interventions under investigation include: Placebo (DRUG), Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT01172652?
This trial is sponsored by VA Palo Alto Health Care System, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01172652 being conducted?
This trial has 3 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.